Skip to content

Preoperative Percutaneous Radiofrequency Ablation of Primary and Secondary Lung Tumors

Evaluation of Effectiveness of Preoperative Percutaneous Radiofrequency Ablation of Primary and Secondary Lung Tumors

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00610844
Enrollment
9
Registered
2008-02-08
Start date
2004-04-30
Completion date
Unknown
Last updated
2008-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Lung Metastasis

Keywords

lung cancer, lung metastasis, radiofrequency ablation

Brief summary

The purpose of the study is to evaluate the effectiveness of radiofrequency ablation by pathological correlation and to characterize the tissue response after treatment of primary and secondary pulmonary tumors.

Detailed description

Thermal ablation therapy is an increasingly performed technique in the local tumor treatment. Among these techniques, image-guided radiofrequency (RF) ablation attained widespread consideration in the therapy of liver tumors and osteoid osteoma. Promising results of hepatic RF ablation raised expectations to utilize the advantages of image-guided ablation therapy for the treatment of pulmonary malignancies. The purpose of the study is to evaluate the effectiveness of radiofrequency ablation by pathological correlation and to characterize the tissue response after treatment of primary and secondary pulmonary tumors. Computed tomography-guided RF ablation is performed in local or general anesthesia, followed by surgical resection three days later. An analysis of complete RF ablation and a characterization of tissue response is performed by hematoxylin and eosin staining, immunostaining, and electron microscopy. Adverse effects and complications are recorded.

Interventions

PROCEDUREpulmonary radiofrequency ablation

CT-guided pulmonary radiofrequency ablation

Sponsors

University Hospital Tuebingen
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Signed informed consent for radiofrequency ablation and surgery * Maximum of 3 lung tumors * Maximum tumor size 5 cm * Must be able to receive standard surgery

Exclusion criteria

* Pathological coagulation tests * Pregnant or breast feeding * Maximum tumor size more than 5 cm * Bilateral secondary lung cancer with more than 3 tumors * Inoperable patient

Design outcomes

Primary

MeasureTime frame
rate of incomplete treated tumors3 days

Secondary

MeasureTime frame
pathologic tissue changes, rate of major and minor complications6 months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026